Liver disease is the third leading cause of premature death in the UK, and non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are now the leading causes of liver disease in Western countries.
At Aquila, we understand the importance of liver disease research to our clients. Understanding the mechanism of these diseases is the priority in addressing the urgent unmet need for NASH therapies.
We are developing a suite of in vitro, ex vivo and in vivo assays with customisable endpoints to study liver disease e.g. transition assays using primary hepatic stellate cells (HSCs) and precision cut liver slices.
Leverage our expertise in primary cell assays, immunology and access to patient tissue, combined with world-leading expertise in FACS, ELISA, specialist multiplex histology and gene expression (qPCR, RNA-sequencing) to accelerate your liver disease drug discovery pipeline today.
Contact us to find out how our liver fibrosis research services can support your liver disease programs.